Eli Lilly Kisunla approved in Japan for early Symptomatic Alzheimer's disease

Japan is the second major market in which Kisunla has been approved for use. In Japan, by 2030, the number of patients with dementia is estimated to be more than 5 million, and AD is the most common cause of dementia, accounting for more than 67% of cases. The number of AD patients is expected to increase significantly compared with other dementias.

"Lilly scientists have been dedicated to research in Alzheimer's disease for more than 35 years, and this news is testament to their ingenuity, perseverance, and commitment to helping people with this disease," said Ilya Yuffa executive vice president and president of Lilly International, Eli Lilly and Company. "Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer's disease by significantly slowing cognitive and functional decline in our TRAILBLAZER-ALZ 2 study, which included participants from Japan. People around the world want and deserve access to treatment options for this devastating disease. The news is another critical step in ensuring patients with Alzheimer's disease can receive treatment with these first class of amyloid therapies, which could give them more time to do what matters most to them."

Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. The excessive buildup of amyloid plaques in the brain may lead to memory and thinking issues associated with Alzheimer's disease. Kisunla can help the body remove the excessive buildup of amyloid plaques and slow the decline that may diminish people's ability to remember new information, important dates, and appointments; plan and organize; make meals; use household appliances; manage finances; and be left alone.

"Alzheimer's disease is a significant healthcare burden in Japan due to the rapidly aging population. We are excited to make Kisunla available in Japan as a new treatment option for early symptomatic Alzheimer's disease," said Yanping Wang, senior vice president of Drug Development and Medical Affairs at Eli Lilly Japan. "Patients treated with Kisunla may have the option to stop treatment once the amyloid plaques are removed, which could help reduce the infusion burden for eligible patients."